Publication: Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients
| dc.contributor.author | Tajuelo, Ana | |
| dc.contributor.author | Carretero, Octavio | |
| dc.contributor.author | Garcia-Rios, Estefani | |
| dc.contributor.author | Lopez-Siles, Mireia | |
| dc.contributor.author | Cano, Olga | |
| dc.contributor.author | Vazquez-Alcaraz, Monica | |
| dc.contributor.author | Mas-Lloret, Vicente | |
| dc.contributor.author | Rodríguez-Goncer, Isabel | |
| dc.contributor.author | Lalueza, Antonio | |
| dc.contributor.author | López-Medrano, Francisco | |
| dc.contributor.author | Juan, Rafael San | |
| dc.contributor.author | Fernández-Ruiz, Mario | |
| dc.contributor.author | Aguado, José María | |
| dc.contributor.author | McConnell, Michael J | |
| dc.contributor.author | Perez-Romero, Pilar | |
| dc.contributor.funder | Fundación Mutua Madrileña | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | |
| dc.contributor.funder | RETICS-Investigación en Patología Infecciosa (REIPI-ISCIII) (España) | |
| dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
| dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | |
| dc.contributor.funder | Comunidad de Madrid (España) | |
| dc.contributor.funder | Unión Europea. Fondo Social Europeo (ESF/FSE) | |
| dc.contributor.funder | Plan Nacional de I+D+i (España) | |
| dc.date.accessioned | 2022-08-05T12:25:57Z | |
| dc.date.available | 2022-08-05T12:25:57Z | |
| dc.date.issued | 2022-04-25 | |
| dc.description | Erratum for: Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients. Tajuelo A, Carretero O, García-Ríos E, López-Siles M, Cano O, Vázquez M, Más V, Rodríguez-Goncer I, Lalueza A, López-Medrano F, Juan RS, Fernández-Ruiz M, Aguado JM, McConnell MJ, Pérez-Romero P. Front Immunol. 2022 Apr 25;13:878812. doi: 10.3389/fimmu.2022.878812. eCollection 2022. PMID: 35547738 Free PMC article. | |
| dc.description.abstract | Introduction: There is robust evidence indicating that the SARS-CoV-2-specific humoral response is associated with protection against severe disease. However, relatively little data exist regarding how the humoral immune response at the time of hospital admission correlates with disease severity in unimmunized patients. Our goal was toidentify variables of the humoral response that could potentially serve as prognostic markers for COVID-19 progressionin unvaccinated SARS-CoV-2 patients. Methods: A prospective cross-sectional study was carried out in a cohort of 160 unimmunized, adult COVID-19 patients from the Hospital Universitario 12Octubre. Participants were classified into four clinical groups based on disease severity: non-survivors with respiratory failure (RF), RF survivors, patients requiring oxygen therapy and those not receiving oxygen therapy. Serum samples were taken on admission and IgM, IgG, IgG subclass antibody titers were determined by ELISA, and neutralizing antibody titersusing a surrogate neutralization assay. The differences in the antibody titers between groups and the association between the clinical and analytical characteristics of the patients and the antibody titers were analyzed. Results: Patients that developed RF and survived had IgM titers that were 2-fold higher than non-survivors (p = 0.001), higher levels of total IgG than those who developed RF and succumbed to infection (p< 0.001), and than patients who required oxygen therapy (p< 0.05), and had 5-fold higher IgG1 titers than RF non-survivors (p< 0.001) and those who needed oxygen therapy (p< 0.001), and 2-fold higher than patients that did not require oxygen therapy during admission (p< 0.05). In contrast, RF non-survivorshad the lowest neutralizing antibodylevels, which were significantly lower compared those with RF that survived (p = 0.03). A positive correlation was found between IgM, total IgG, IgG1 and IgG3 titers and neutralizing antibody titers in the total cohort (p ≤ 0.0036). Conclusions: We demonstrate that patients with RF that survived infection had significantly higher IgM, IgG, IgG1 and neutralizing titers compared to patients with RF that succumb to infection, suggesting that using humoral response variables could be used as a prognostic marker for guiding the clinical management of unimmunized patients admitted to the hospital for SARS-CoV-2 infection. | es_ES |
| dc.description.peerreviewed | Sí | es_ES |
| dc.description.sponsorship | This work was supported by Mutua Madrileña Foundation (2020/0056) “Plan Nacional de I+D+I” and Instituto de Salud Carlos III (COVID-19 Research Call COV20/00181 and COV20_00679), Subdirección General de Redes y Centros de Investigación Cooperativa, Spanish Ministry of Science and Innovation, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016) - co-financed by the European Development Regional Fund (EDRF) and the European Social Fund (ESF) "A way to achieve Europe- The ESF invests in your future". Red de Enfermedades Infecciosas (CIBERINFEC), CB21/13/00079. EG-R is supported by the Sara Borrell Program (CD18CIII/00007), MLS is supported by the Sara Borrell Program (CD17CIIII/00017), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades., and AT is supported by the Garantía Juvenil Program of the Comunidad Autonoma de Madrid. IRG holds a research training contract “Río Hortega” (CM19/00163) and MFR a research contract “Miguel Servet” (CP18/00073), both from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation. | es_ES |
| dc.format.page | 878812 | es_ES |
| dc.format.volume | 13 | es_ES |
| dc.identifier.citation | Front Immunol. 2022 Apr 25;13:878812. | es_ES |
| dc.identifier.doi | 10.3389/fimmu.2022.878812 | es_ES |
| dc.identifier.e-issn | 1664-3224 | es_ES |
| dc.identifier.journal | Frontiers in Immunology | es_ES |
| dc.identifier.pubmedID | 35547738 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/20.500.12105/14872 | |
| dc.language.iso | eng | es_ES |
| dc.publisher | Frontiers Media | |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0004/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/COV20/00679 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CB21/13/00079 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CD18CIII/00007 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CD17CIIII/00017 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CM19/00163 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CP18/00073 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/COV20/00181 | es_ES |
| dc.relation.publisherversion | https://doi.org/10.3389/fimmu.2022.878812 | es_ES |
| dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
| dc.repisalud.institucion | ISCIII | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Atribución 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | COVID disease severity | es_ES |
| dc.subject | IgG | es_ES |
| dc.subject | IgM 2 | es_ES |
| dc.subject | SARS-CoV-2 | es_ES |
| dc.subject | Humoral response | es_ES |
| dc.subject.mesh | COVID-19 | es_ES |
| dc.subject.mesh | Respiratory Insufficiency | es_ES |
| dc.subject.mesh | Adult | es_ES |
| dc.subject.mesh | Antibodies, Neutralizing | es_ES |
| dc.subject.mesh | Antibodies, Viral | es_ES |
| dc.subject.mesh | Cross-Sectional Studies | es_ES |
| dc.subject.mesh | Humans | es_ES |
| dc.subject.mesh | Immunity, Humoral | es_ES |
| dc.subject.mesh | Immunoglobulin G | es_ES |
| dc.subject.mesh | Immunoglobulin M | es_ES |
| dc.subject.mesh | Oxygen | es_ES |
| dc.subject.mesh | Prospective Studies | es_ES |
| dc.subject.mesh | Research Report | es_ES |
| dc.subject.mesh | SARS-CoV-2 | es_ES |
| dc.title | Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients | es_ES |
| dc.type | journal article | es_ES |
| dc.type.hasVersion | VoR | es_ES |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 78ddc608-8ded-4d2f-bb25-ec2792783993 | |
| relation.isAuthorOfPublication | 50b540df-28b6-4182-a1ee-d7ee50b0114e | |
| relation.isAuthorOfPublication | 56aad11f-59aa-480b-ade4-8b7200f31d08 | |
| relation.isAuthorOfPublication | 05b142a5-2280-41d5-8af9-1119c5338244 | |
| relation.isAuthorOfPublication | 4f567393-69b2-45f3-8951-778808a00edc | |
| relation.isAuthorOfPublication | cdaece7c-45bc-4988-bb11-429e0b25402b | |
| relation.isAuthorOfPublication | 1d2e9ea7-be75-4b13-a09e-656f8f304a14 | |
| relation.isAuthorOfPublication | 619c44d6-0adf-4ccf-9b6a-66663bad5429 | |
| relation.isAuthorOfPublication.latestForDiscovery | 78ddc608-8ded-4d2f-bb25-ec2792783993 | |
| relation.isFunderOfPublication | 965c36a0-b77d-4aed-b64e-2bca07b473e6 | |
| relation.isFunderOfPublication | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isFunderOfPublication | 289dce42-6a28-4892-b0a8-c70c46cbb185 | |
| relation.isFunderOfPublication | 59c823cb-42b5-4b1b-a401-bf53ee82c170 | |
| relation.isFunderOfPublication | efa64f05-b985-4984-8f1e-5fc4ef21f502 | |
| relation.isFunderOfPublication | 1aef4c3b-1ee5-4534-83b4-3f3811c67280 | |
| relation.isFunderOfPublication | c87c70a3-e023-4b6b-ac25-1b2d1b483786 | |
| relation.isFunderOfPublication | 36ca2ebf-c6c3-4f53-8618-500af224a277 | |
| relation.isFunderOfPublication | 0e5401ef-8ce7-439f-85e0-4e3550b5fade | |
| relation.isFunderOfPublication.latestForDiscovery | 965c36a0-b77d-4aed-b64e-2bca07b473e6 | |
| relation.isPublisherOfPublication | 9f9fa5ea-093b-43d8-bf2c-5bd65d08a802 | |
| relation.isPublisherOfPublication.latestForDiscovery | 9f9fa5ea-093b-43d8-bf2c-5bd65d08a802 |
Files
Original bundle
1 - 3 of 3
Loading...
- Name:
- BriefResearchReportVirus_2022.pdf
- Size:
- 2.03 MB
- Format:
- Adobe Portable Document Format
- Description:
- Artículo principal
Loading...
- Name:
- BriefResearchReportVirusSupplementaryMaterial_2022.pdf
- Size:
- 680.53 KB
- Format:
- Adobe Portable Document Format
- Description:
- Supplementary Information
Loading...
- Name:
- CorrigendumBriefResearchReport_2022.pdf
- Size:
- 181.73 KB
- Format:
- Adobe Portable Document Format
- Description:
- Coprrección de errores


